The long-acting version of a popular diabetes drug has received positive results from a phase III study released today.
Long-acting Byetta LAR, developed by Eli Lilly in conjunction with Amylin Pharmaceuticals, will allow diabetics to control blood sugar levels efficiently over a long period of time.
The drug is administered as a once-weekly injection. According to the recent study, type 2 diabetics achieve a 1.9 per cent improvement in A1C levels. For patients who use regular byetta, the improvement stands at 1.5 per cent, according to trials.
One of the major side effects of the drug is weight loss, and the companies have worked to reduce the level of nausea felt. In response to the news, shares in Amylin climbed.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…